Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation

Table 1

Pediatric and adult PTLD.

	Pediatric PTLD		Adult PTLD
		Reference		Reference
EBV serostatus at transplantation
Negative	78%	[10]	13%*	[125]
Positive	22%		87%*
EBV association of PTLD	90%	[10]	45% (−69%*)	[60, 125]
Histology
Polymorphic	16%	[10]	27%*	[125]
Monomorphic	72%		65%*
Hodgkin’s disease	9%		7%*
B-cell origin	97%		93%*
T-cell origin	3%		6%*
First-line treatment (B-cell disease)	Rituximab +/− reduced intensity chemotherapy	[63]	Rituximab +/− standard chemotherapy	[60]
Prognosis	2-year overall survival 80–90%	[63]	2-year overall survival 60–70%	[60]
Incidence according to transplanted organ
Kidney	2%-3%	[21, 22]	1.0%–2.3%	[4]
Liver	5%–10%	[24–26]	1.0%–2.3%
Heart	~6%	[16]	1.0%–6.3%
Lung	~15%	[27, 28]	2.4%–10.0%
Small bowl	~20%	[29]	20%

∗Adult data derived from a KTx population.